Crospon establishes US Operation in California

Experienced Vice President of Sales for Americas market appointed

Monday 9^th February 2009 – Crospon, a medical device developer based in Galway, Ireland today announced the appointment of Larry Fulton as Vice President of Sales - Americas located at the company’s newly established US operation in Carlsbad, California. 

Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area.

Announcing the appointment, John O’Dea, CEO Crospon, said, “We are delighted to announce that Larry has agreed to head up our sales activities in the Americas. We are coming into a critical time for Crospon and our EndoFLIP^® system as we prepare for market entry. Larry brings with him considerable industry experience with particular focus on the challenges of moving from concept to commercialisation. This appointment significantly strengthens the Crospon senior management team and we are looking forward to the milestones ahead in 2009.”

Heading up Crospon’s sales operation for the Americas, Fulton brings with him over 17 years of experience in minimally invasive surgery and most recently he worked with start up company, Endogastric Solutions Inc where as Director of Sales, US  Mexico and Canada, he oversaw the successful national sales introduction of two new medical device product lines. Larry’s experience also includes six years with the Inamed Health Division of the Allergan Corporation where he held the position of National Sales Manager introducing the LapBand System in the US and five years with Johnson & Johnson Ethicon Endo Surgery. 

Commenting on his appointment Fulton said, "I am extremely excited about joining Crospon. We are looking forward to introducing a revolutionary technology in the near future that has the potential to make a significant impact. EndoFLIP^® is a device the market has needed and is ready for."

In January, Crospon announced that its EndoFLIP^® system had received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish Notified Body, in accordance with the European Medical Device Directive. CE Mark certification represented an important step in the company’s development and ensures Crospon remains on schedule to release the EndoFLIP® system into the European market by the end of the first half of 2009.

In December 2008, Crospon announced that it had completed an additional €500,000 funding round, following on from the completion of a €3m round of financing earlier that year. This additional funding will be primarily used for the completion of development, manufacturing startup and preparation to market of the EndoFLIP^® system. EndoFLIP^® is used to enhance diagnosis and assist in the surgical treatment of gastroesophageal reflux disorder (GERD). For further information please view www.endoflip.com. The EndoFLIP^® system is the first is a range of products the company plans to bring to market.